Bristol-Myers Squibb (BMY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Bristol-Myers Squibb Revenue Highlights

Latest Revenue (Y)

$48.30B

Latest Revenue (Q)

$11.89B

Main Segment (Y)

Eliquis

Main Geography (Y)

UNITED STATES

Bristol-Myers Squibb Revenue by Period

Bristol-Myers Squibb Revenue by Year

Date	Revenue	Change
2024-12-31	$48.30B	7.32%
2023-12-31	$45.01B	-2.50%
2022-12-31	$46.16B	-0.49%
2021-12-31	$46.38B	9.09%
2020-12-31	$42.52B	62.62%
2019-12-31	$26.14B	15.89%
2018-12-31	$22.56B	8.59%
2017-12-31	$20.78B	6.94%
2016-12-31	$19.43B	17.31%
2015-12-31	$16.56B	4.29%
2014-12-31	$15.88B	-3.09%
2013-12-31	$16.39B	-7.01%
2012-12-31	$17.62B	-17.05%
2011-12-31	$21.24B	9.03%
2010-12-31	$19.48B	3.59%
2009-12-31	$18.81B	-8.69%
2008-12-31	$20.60B	6.46%
2007-12-31	$19.35B	8.00%
2006-12-31	$17.91B	-6.73%
2005-12-31	$19.21B	-0.89%
2004-12-31	$19.38B	-7.25%
2003-12-31	$20.89B	15.32%
2002-12-31	$18.12B	-6.71%
2001-12-31	$19.42B	6.63%
2000-12-31	$18.22B	-9.92%
1999-12-31	$20.22B	10.60%
1998-12-31	$18.28B	9.48%
1997-12-31	$16.70B	10.86%
1996-12-31	$15.06B	9.43%
1995-12-31	$13.77B	14.88%
1994-12-31	$11.98B	5.00%
1993-12-31	$11.41B	-

Bristol-Myers Squibb generated $48.30B in revenue during NA 2024, up 7.32% compared to the previous quarter, and up 184.74% compared to the same period a year ago.

Bristol-Myers Squibb Revenue by Quarter

Date	Revenue	Change
2024-09-30	$11.89B	-2.53%
2024-06-30	$12.20B	2.83%
2024-03-31	$11.87B	3.38%
2023-12-31	$11.48B	4.66%
2023-09-30	$10.97B	-2.32%
2023-06-30	$11.23B	-0.98%
2023-03-31	$11.34B	-0.60%
2022-12-31	$11.41B	1.68%
2022-09-30	$11.22B	-5.63%
2022-06-30	$11.89B	2.05%
2022-03-31	$11.65B	-2.81%
2021-12-31	$11.98B	3.11%
2021-09-30	$11.62B	-0.68%
2021-06-30	$11.70B	5.69%
2021-03-31	$11.07B	0.05%
2020-12-31	$11.07B	5.01%
2020-09-30	$10.54B	4.06%
2020-06-30	$10.13B	-6.05%
2020-03-31	$10.78B	35.70%
2019-12-31	$7.95B	32.26%
2019-09-30	$6.01B	-4.24%
2019-06-30	$6.27B	5.96%
2019-03-31	$5.92B	-0.89%
2018-12-31	$5.97B	4.96%
2018-09-30	$5.69B	-0.23%
2018-06-30	$5.70B	9.84%
2018-03-31	$5.19B	-4.70%
2017-12-31	$5.45B	3.71%
2017-09-30	$5.25B	2.14%
2017-06-30	$5.14B	4.36%
2017-03-31	$4.93B	-5.99%
2016-12-31	$5.24B	6.52%
2016-09-30	$4.92B	1.05%
2016-06-30	$4.87B	10.93%
2016-03-31	$4.39B	2.43%
2015-12-31	$4.29B	5.36%
2015-09-30	$4.07B	-2.26%
2015-06-30	$4.16B	3.02%
2015-03-31	$4.04B	-5.10%
2014-12-31	$4.26B	8.59%
2014-09-30	$3.92B	0.82%
2014-06-30	$3.89B	2.05%
2014-03-31	$3.81B	-14.19%
2013-12-31	$4.44B	9.25%
2013-09-30	$4.07B	0.42%
2013-06-30	$4.05B	5.66%
2013-03-31	$3.83B	-8.59%
2012-12-31	$4.19B	12.18%
2012-09-30	$3.74B	-15.91%
2012-06-30	$4.44B	-15.39%
2012-03-31	$5.25B	-3.72%
2011-12-31	$5.45B	2.04%
2011-09-30	$5.34B	-1.64%
2011-06-30	$5.43B	8.44%
2011-03-31	$5.01B	-1.96%
2010-12-31	$5.11B	6.52%
2010-09-30	$4.80B	0.63%
2010-06-30	$4.77B	-0.81%
2010-03-31	$4.81B	64.51%
2009-12-31	$2.92B	-46.75%
2009-09-30	$5.49B	1.91%
2009-06-30	$5.38B	7.36%
2009-03-31	$5.01B	-4.46%
2008-12-31	$5.25B	-0.10%
2008-09-30	$5.25B	0.98%
2008-06-30	$5.20B	0.42%
2008-03-31	$5.18B	5.86%
2007-12-31	$4.89B	-

Bristol-Myers Squibb generated $11.89B in revenue during Q3 2024, up -2.53% compared to the previous quarter, and up 105.93% compared to the same period a year ago.

Bristol-Myers Squibb Revenue Breakdown

Bristol-Myers Squibb Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
Abraxane	$875.00M	$811.00M	$1.18B	$1.25B	$166.00M
Zeposia	$566.00M	$250.00M	$134.00M	$12.00M	-
Yervoy	$2.53B	$2.13B	$2.03B	$1.68B	$1.49B
Sprycel	$1.29B	$2.17B	$2.12B	$2.14B	$2.11B
Sotyktu	$246.00M	$8.00M	-	-	-
Revlimid	$5.77B	$9.98B	$12.82B	$12.11B	$1.30B
Reblozyl	$1.77B	$717.00M	$551.00M	$274.00M	-
Pomalyst/Imnovid	$3.54B	$3.50B	$3.33B	$3.07B	$322.00M
Orencia	$3.68B	$3.46B	$3.31B	$3.16B	$2.98B
Opdualag	$928.00M	$252.00M	-	-	-
Opdivo	$9.30B	$8.25B	$7.52B	$6.99B	$7.20B
Eliquis	$13.33B	$11.79B	$10.76B	$9.17B	$7.93B
Camzyos	$602.00M	$24.00M	-	-	-
Breyanzi	$747.00M	$182.00M	$87.00M	-	-
Augtyro	$38.00M	-	-	-	-
Abecma	$406.00M	$388.00M	$164.00M	-	-
Onureg	-	$124.00M	$73.00M	$17.00M	-
Inrebic	-	$85.00M	$74.00M	$55.00M	$5.00M
Mature Products And All Other	-	$1.75B	$1.90B	$1.31B	$1.67B
Empliciti	-	$296.00M	$334.00M	$381.00M	$357.00M
Vidaza	-	-	-	$455.00M	$58.00M
Baraclude	-	-	-	$447.00M	$555.00M

Bristol-Myers Squibb's latest annual revenue breakdown by segment (product or service), as of Dec 24: Eliquis (29.22%), Opdivo (20.39%), Revlimid (12.65%), Orencia (8.07%), Pomalyst/Imnovid (7.77%), Yervoy (5.54%), Reblozyl (3.89%), Sprycel (2.82%), Opdualag (2.03%), Abraxane (1.92%), Breyanzi (1.64%), Camzyos (1.32%), Zeposia (1.24%), Abecma (0.89%), Sotyktu (0.54%), and Augtyro (0.08%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
Augtyro	$10.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Eliquis	$3.00B	$3.20B	$3.42B	$2.69B	$2.65B	$3.23B	$3.21B	$2.67B	$2.41B	$2.79B	$2.89B	$2.27B	$2.10B	$2.16B	$2.64B	$2.03B	$1.93B	$2.04B	$1.93B	$1.58B
Abraxane	$253.00M	$258.00M	$239.00M	$179.00M	$177.00M	$241.00M	$214.00M	$305.00M	$266.00M	$296.00M	$314.00M	$297.00M	$342.00M	$308.00M	$300.00M	-	-	-	-	-
Pomalyst/Imnovid	$898.00M	$847.00M	$832.00M	$877.00M	$886.00M	$908.00M	$826.00M	$854.00M	$851.00M	$854.00M	$773.00M	$835.00M	$777.00M	$745.00M	$713.00M	-	-	-	-	-
Reblozyl	$447.00M	$234.00M	$206.00M	$199.00M	$190.00M	$172.00M	$156.00M	$151.00M	$160.00M	$128.00M	$112.00M	$115.00M	$96.00M	$55.00M	$8.00M	-	-	-	-	-
Revlimid	$1.41B	$1.47B	$1.75B	$2.26B	$2.42B	$2.50B	$2.80B	$3.33B	$3.35B	$3.20B	$2.94B	$3.28B	$3.03B	$2.88B	$2.92B	-	-	-	-	-
Sotyktu	$66.00M	$25.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sprycel	$290.00M	$458.00M	$429.00M	$578.00M	$560.00M	$544.00M	$483.00M	$555.00M	$551.00M	$541.00M	$470.00M	$564.00M	$544.00M	$511.00M	$521.00M	$549.00M	$558.00M	$544.00M	$459.00M	$491.00M
Yervoy	$642.00M	$585.00M	$508.00M	$568.00M	$523.00M	$525.00M	$515.00M	$545.00M	$515.00M	$510.00M	$456.00M	$471.00M	$446.00M	$369.00M	$396.00M	$385.00M	$353.00M	$367.00M	$384.00M	$382.00M
Orencia	$936.00M	$927.00M	$764.00M	$913.00M	$883.00M	$876.00M	$792.00M	$864.00M	$870.00M	$814.00M	$758.00M	$867.00M	$826.00M	$750.00M	$714.00M	$792.00M	$767.00M	$778.00M	$640.00M	$675.00M
Opdualag	$233.00M	$154.00M	$117.00M	$104.00M	$84.00M	$58.00M	$6.00M	-	-	-	-	-	-	-	-	-	-	-	-	-
Opdivo	$2.36B	$2.15B	$2.20B	$2.22B	$2.05B	$2.06B	$1.92B	$1.99B	$1.91B	$1.91B	$1.72B	$1.79B	$1.78B	$1.65B	$1.77B	$1.76B	$1.82B	$1.82B	$1.80B	$1.79B
Abecma	$124.00M	$132.00M	$147.00M	$125.00M	$107.00M	$89.00M	$67.00M	$69.00M	$71.00M	$24.00M	-	-	-	-	-	-	-	-	-	-
Zeposia	$147.00M	$100.00M	$78.00M	$79.00M	$69.00M	$66.00M	$36.00M	$48.00M	$40.00M	$28.00M	$18.00M	$9.00M	$2.00M	$1.00M	-	-	-	-	-	-
Breyanzi	$224.00M	$100.00M	$71.00M	$55.00M	$44.00M	$39.00M	$44.00M	$40.00M	$30.00M	$17.00M	-	-	-	-	-	-	-	-	-	-
Camzyos	$156.00M	$46.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Onureg	-	$44.00M	$34.00M	$37.00M	$32.00M	$32.00M	$23.00M	$25.00M	$21.00M	$12.00M	$15.00M	$14.00M	$3.00M	-	-	-	-	-	-	-
Mature and Other Brands	-	$472.00M	$467.00M	$441.00M	$435.00M	$462.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inrebic	-	$27.00M	$25.00M	$23.00M	$21.00M	$23.00M	$18.00M	$20.00M	$22.00M	$16.00M	$16.00M	$15.00M	$13.00M	$15.00M	$12.00M	-	-	-	-	-
Empliciti	-	-	-	$71.00M	$73.00M	$77.00M	$75.00M	$81.00M	$82.00M	$86.00M	$85.00M	$91.00M	$96.00M	$97.00M	$97.00M	$94.00M	$89.00M	$91.00M	$83.00M	$59.00M
Mature Products And All Other	-	-	-	-	-	-	-	$903.00M	$339.00M	$319.00M	$339.00M	$279.00M	$287.00M	$331.00M	$418.00M	$356.00M	$350.00M	$481.00M	$487.00M	-
Baraclude	-	-	-	-	-	-	-	-	$105.00M	$109.00M	$113.00M	$104.00M	$100.00M	$121.00M	$122.00M	$122.00M	$145.00M	$147.00M	$141.00M	$175.00M
Vidaza	-	-	-	-	-	-	-	-	$36.00M	$45.00M	$54.00M	$65.00M	$106.00M	$126.00M	$158.00M	-	-	-	-	-
Hepatitis C Portfolio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-2.00M
Reyataz	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$87.00M
Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$382.00M
Sustiva Franchise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$72.00M

Bristol-Myers Squibb's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Eliquis (26.80%), Opdivo (21.07%), Revlimid (12.61%), Orencia (8.36%), Pomalyst/Imnovid (8.02%), Yervoy (5.73%), Reblozyl (3.99%), Sprycel (2.59%), Abraxane (2.26%), Opdualag (2.08%), Breyanzi (2.00%), Camzyos (1.39%), Zeposia (1.31%), Abecma (1.11%), Sotyktu (0.59%), and Augtyro (0.09%).

Bristol-Myers Squibb Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$34.10B	$31.83B	$29.21B	$26.58B	$15.34B
Other Region	$996.00M	$834.00M	$852.00M	$631.00M	$524.00M
European Union	-	$13.50B	$10.69B	$9.85B	$6.27B
Europe	-	$13.50B	-	-	-
Rest Of World	-	-	$5.63B	$5.46B	$4.01B

Bristol-Myers Squibb's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (97.16%), and Other Region (2.84%).

Quarterly Revenue by Country

Country	Sep 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
Other Region	$271.00M	$175.00M	$155.00M	$200.00M	$215.00M	$192.00M	$227.00M	$221.00M	$276.00M	$191.00M	$164.00M	$162.00M	$184.00M	$172.00M	$113.00M	$166.00M	$114.00M	$127.00M	$117.00M	-
UNITED STATES	$8.23B	$7.89B	$8.03B	$7.92B	$7.94B	$8.27B	$7.69B	$7.52B	$7.30B	$7.39B	$7.01B	$6.78B	$6.54B	$6.49B	$6.77B	$4.75B	$3.47B	$3.67B	$3.45B	$3.23B
Rest Of World	$3.39B	$3.16B	$1.31B	$1.46B	$1.39B	$1.44B	$1.35B	$1.43B	$1.36B	$1.33B	$1.33B	$1.18B	$976.00M	$988.00M	$874.00M	$932.00M	-	-	-	-
Europe	-	-	-	-	-	-	$2.41B	$2.66B	$2.69B	$1.36B	-	-	-	-	-	-	-	-	-	-
European Union	-	-	-	-	-	-	-	-	-	-	$2.55B	$2.70B	$2.45B	$2.14B	$2.57B	$1.85B	$1.45B	$1.49B	$1.48B	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$159.00M

Bristol-Myers Squibb's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (69.22%), Rest Of World (28.50%), and Other Region (2.28%).

Bristol-Myers Squibb Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
MRK	Merck	$64.17B	$16.66B
PFE	Pfizer	$63.63B	$17.70B
JNJ	Johnson & Johnson	$61.35B	$22.47B
BMY	Bristol-Myers Squibb	$48.30B	$11.89B
LLY	Eli Lilly and	$45.04B	$11.44B
AMGN	Amgen	$33.42B	$8.50B
GILD	Gilead Sciences	$28.75B	$7.55B
BIIB	Biogen	$9.68B	$2.47B
ABBV	AbbVie	-	$14.46B

BMY Revenue FAQ

What is Bristol-Myers Squibb’s yearly revenue?

Bristol-Myers Squibb's yearly revenue for 2024 was $48.3B, representing an increase of 7.32% compared to 2023. The company's yearly revenue for 2023 was $45.01B, representing a decrease of -2.50% compared to 2022. BMY's yearly revenue for 2022 was $46.16B, representing a decrease of -0.49% compared to 2021.

What is Bristol-Myers Squibb’s quarterly revenue?

Bristol-Myers Squibb's quarterly revenue for Q3 2024 was $11.89B, a -2.53% decrease from the previous quarter (Q2 2024), and a 8.44% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $12.2B, a 2.83% increase from the previous quarter (Q1 2024), and a 8.69% increase year-over-year (Q2 2023). BMY's quarterly revenue for Q1 2024 was $11.86B, a 3.38% increase from the previous quarter (Q4 2023), and a 4.66% increase year-over-year (Q1 2023).

What is Bristol-Myers Squibb’s revenue growth rate?

Bristol-Myers Squibb's revenue growth rate for the last 3 years (2022-2024) was 4.64%, and for the last 5 years (2020-2024) was 13.60%.

What are Bristol-Myers Squibb’s revenue streams?

Bristol-Myers Squibb's revenue streams in c 24 are Abraxane, Zeposia, Yervoy, Sprycel, Sotyktu, Revlimid, Reblozyl, Pomalyst/Imnovid, Orencia, Opdualag, Opdivo, Eliquis, Camzyos, Breyanzi, Augtyro, and Abecma. Abraxane generated $875M in revenue, accounting 1.92% of the company's total revenue, up 7.89% year-over-year. Zeposia generated $566M in revenue, accounting 1.24% of the company's total revenue, up 126.40% year-over-year. Yervoy generated $2.53B in revenue, accounting 5.54% of the company's total revenue, up 18.72% year-over-year. Sprycel generated $1.29B in revenue, accounting 2.82% of the company's total revenue, down -40.60% year-over-year. Sotyktu generated $246M in revenue, accounting 0.54% of the company's total revenue, up 2975.00% year-over-year. Revlimid generated $5.77B in revenue, accounting 12.65% of the company's total revenue, down -42.14% year-over-year. Reblozyl generated $1.77B in revenue, accounting 3.89% of the company's total revenue, up 147.28% year-over-year. Pomalyst/Imnovid generated $3.54B in revenue, accounting 7.77% of the company's total revenue, up 1.37% year-over-year. Orencia generated $3.68B in revenue, accounting 8.07% of the company's total revenue, up 6.29% year-over-year. Opdualag generated $928M in revenue, accounting 2.03% of the company's total revenue, up 268.25% year-over-year. Opdivo generated $9.3B in revenue, accounting 20.39% of the company's total revenue, up 12.79% year-over-year. Eliquis generated $13.33B in revenue, accounting 29.22% of the company's total revenue, up 13.10% year-over-year. Camzyos generated $602M in revenue, accounting 1.32% of the company's total revenue, up 2408.33% year-over-year. Breyanzi generated $747M in revenue, accounting 1.64% of the company's total revenue, up 310.44% year-over-year. Augtyro generated $38M in revenue, accounting 0.08% of the company's total revenue Abecma generated $406M in revenue, accounting 0.89% of the company's total revenue, up 4.64% year-over-year.

What is Bristol-Myers Squibb’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Bristol-Myers Squibb was Eliquis. This segment made a revenue of $13.33B, representing 29.22% of the company's total revenue.